ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Inclusion Criteria: * Active subfoveal NVAMD Exclusion Criteria: * History or evidence of severe cardiac disease * Any major surgical procedure within one month of trial entry * Subjects with a clinically significant laboratory value * Any treatment with an investigational agent in the past 60 days for any condition * Women who are pregnant or nursing * Known serious allergies to the fluorescein dye used in angiography, povidone iodine, to the components of the ranibizumab formulation, or to the components of the Zimura formulation * Any prior treatment for AMD other than oral supplements of vitamins and minerals